CLINICAL TRIALS PROFILE FOR TYMLOS
✉ Email this page to a colleague
All Clinical Trials for TYMLOS
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03841058 ↗ | Phase II Trial of Abaloparatide vs. Placebo in Post-Menopausal Women Receiving Initial Spinal Fusion Surgery | Recruiting | Hospital for Special Surgery, New York | Phase 2 | 2019-08-14 | This is a prospective randomized, double-blinded, placebo-controlled, phase 2, 12-month pilot to study the efficacy of abaloparatide in postmenopausal women needing lumbar spinal fusion surgery. Seventy-two women with low bone mass who are scheduled to undergo spinal fusion surgery will be randomized 2:1 in a blinded fashion to receive either 80 mcg of abaloparatide subcutaneously (SC) every day or an identical-appearing placebo SC for 6 months. Outcomes include surgical outcome at one year, pain, and fusion bone mass volume (FBMV) as a marker of bone union at 6 months and 1 year. |
| NCT04167163 ↗ | Abaloparatide Before Total Knee Arthroplasty | Recruiting | Radius Health, Inc. | Phase 4 | 2020-01-10 | The investigator hypothesizes that treating osteoporotic patients with abaloparatide prior to and after total knee arthroplasty will significantly reduce the amount of bone loss. |
| NCT04167163 ↗ | Abaloparatide Before Total Knee Arthroplasty | Recruiting | University of Wisconsin, Madison | Phase 4 | 2020-01-10 | The investigator hypothesizes that treating osteoporotic patients with abaloparatide prior to and after total knee arthroplasty will significantly reduce the amount of bone loss. |
| NCT04249232 ↗ | Abaloparatide and Pelvic Fracture Healing | Recruiting | Icahn School of Medicine at Mount Sinai | Phase 2 | 2020-09-17 | This is a prospective randomized, double-blinded, placebo-controlled, phase 2, three-month study of the efficacy of abaloparatide in postmenopausal women and men ≥ 50 years of age with acute fractures of the pelvis (n=78). The primary outcome is CT image based evidence of fracture healing. The secondary aims are pain and physical performance measures at 3 months. This study will be extended with 9 months of open label abaloparatide to determine if any potential differences between the placebo and abaloparatide groups during the 3 months of treatment are evident and persist over time, even in patients who use abaloparatide after the three-month placebo controlled intervention. |
| NCT04249232 ↗ | Abaloparatide and Pelvic Fracture Healing | Recruiting | Lenox Hill Hospital | Phase 2 | 2020-09-17 | This is a prospective randomized, double-blinded, placebo-controlled, phase 2, three-month study of the efficacy of abaloparatide in postmenopausal women and men ≥ 50 years of age with acute fractures of the pelvis (n=78). The primary outcome is CT image based evidence of fracture healing. The secondary aims are pain and physical performance measures at 3 months. This study will be extended with 9 months of open label abaloparatide to determine if any potential differences between the placebo and abaloparatide groups during the 3 months of treatment are evident and persist over time, even in patients who use abaloparatide after the three-month placebo controlled intervention. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TYMLOS
Condition Name
Clinical Trial Locations for TYMLOS
Trials by Country
Clinical Trial Progress for TYMLOS
Clinical Trial Phase
Clinical Trial Sponsors for TYMLOS
Sponsor Name
